목적: 리피오돌은 간암환자의 간동맥으로 투여시 암에 많이 섭취된다. 이 연구에서는 Re-188-황 교질/리피오돌을 제조하여 생체내분포를 보았다. 재료 및 방법: Re-188-황 교질/리피오돌을 마우스의 꼬리정맥으로 주사한후 1 시간 후에 생체내 분포를 확인하였다. 간암을 유발시킨 백서의 좌심실로 Re-188-황 교질/리피오돌을 주사하고 5 분후의 생체내 분포와 간의 자가방사사진을 보았다. 결과: Re-188-황 교질/리피오돌을 마우스의 꼬리정맥으로 주사한 후 1시간(n=3)섭취율(％ ID/organ)은 간에서 5.2±0.7, 폐는 91.0±1.7이었다. 간암을 유발시킨 백서의 좌심실로 Re-188-황 교질/리피오돌을 주사한 후 5 분(n=4)의 정상간의 섭취율(％ ID/g)은 0.41±0.28, 간암은 1.88±1.57, 폐는 1.65±1.54였으며, 자가방사사진에서도 간암부위의 섭취가 정상적인 간조직 보다 증가되었다. 결론: Re-188-황 교질/리피오돌을 동맥으로 투여시 간암부위의 섭취가 정상적인 간조직보다 많아 간암치료용 방사성의약품으로서 사용할 수 있음을 알았다.

Lipiodol is used for targeting liver cancers by administrating through the hepatic artery. In the present study, feasibility of Re-188-sulfur colloid suspension in lipiodol as a liver cancer targeting agent was investigated. Materials and Methods: Re-188-sulfur colloid was prepared, harvested by centrifugation, washed with organic solvent and then suspended into lipiodol. Biodistribution of Re-188-sulfur colloid in normal saline and its suspension in lipiodol in mice after 1 hr of injection through the tail vein were investigated. Biodistribution and autoradiography of tumor-bearing liver was acquired after 5 min post-injection into left ventricle of the tumor-inoculated rats. Results: After 1 hr of injection with Re-188-sulfur colloid suspension in lipiodol through the tail vein in normal mice (n=3), the uptakes in the liver and lung were 5.2±0.7 and 91.0±1.7％ ID/organ, respectively. After 5 min of injection with Re-188-sulfur colloid suspention in lipiodol through the left ventricle in the tumor-inoculated rats (n=4), uptakes in the normal liver, hepatoma, and lung were 0.41±0.28, 1.88±1.57, and 1.65±1.54％ ID/organ, respectively. And autoradiography of hepatoma showed increased uptake than normal liver tissues. Conclusion: Re-188-sulfur colloid suspension in lipiodol injected through the artery shows higher uptake in the hepatoma than normal liver tissue that indicates the feasibility as a new radiopharmaceutical for therapy of hepatoma.